Combination therapy targeting the elevated interleukin‐6 level reduces invasive migration of BRAF inhibitor‐resistant melanoma cells

The identification of novel antimetastatic therapeutic targets is necessary for improved treatment of patients with acquired BRAF inhibitor‐resistant (BRAFi‐R) melanoma, in whom metastasis is a major concern. Our present study focused on the identification of such targets to explore novel antimetast...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohapatra, Purusottam, Prasad, Chandra Prakash, Andersson, Tommy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360505/
https://www.ncbi.nlm.nih.gov/pubmed/30582770
http://dx.doi.org/10.1002/1878-0261.12433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360505/
https://www.ncbi.nlm.nih.gov/pubmed/30582770
http://dx.doi.org/10.1002/1878-0261.12433

Ejemplares similares